13 reports of this reaction
4.8% of all AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE reports
#3 most reported adverse reaction
NEOPLASM MALIGNANT is the #3 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, manufactured by Kenvue Brands LLC. There are 13 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE to NEOPLASM MALIGNANT. This represents approximately 4.8% of all 273 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE who experience neoplasm malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM MALIGNANT is moderately reported among AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE users, representing a notable but not dominant share of adverse events.
In addition to neoplasm malignant, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE:
The following drugs have also been linked to neoplasm malignant in FDA adverse event reports:
NEOPLASM MALIGNANT has been reported as an adverse event in 13 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM MALIGNANT accounts for approximately 4.8% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, making it one of the most commonly reported side effect.
If you experience neoplasm malignant while taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.